Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
28 hedge funds and large institutions have $803K invested in Aevi Genomic Medicine Inc in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 11 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
12.67% less ownership
Funds ownership: 19.02% → 6.35% (-13%)
26% less funds holding
Funds holding: 38 → 28 (-10)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
98% less capital invested
Capital invested by funds: $47.2M → $803K (-$46.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$228K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$55.1K |
| 3 |
VF
Virtu Financial
New York
|
+$53.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AMCA
Arthur M. Cohen & Associates
Northbrook,
Illinois
|
-$38.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.85M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.77M |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$141K |
| 5 |
Millennium Management
New York
|
-$43K |
GNMX Hedge Fund Activity: Q1 2019 in Review
28 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2019, worth a combined $803K — down 98% from $47.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GNMX and 1 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $228K. The largest seller was Arthur M. Cohen & Associates, exiting entirely with an estimated $38.6M sold.
- 28 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2019, down from 38 in Q4 2018.
- Funds reported $803K of Aevi Genomic Medicine Inc stock for Q1 2019, down 98% quarter-over-quarter.
- 1 fund opened new Aevi Genomic Medicine Inc positions in Q1 2019 and 11 closed out, a net change of -10 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2019 was Renaissance Technologies, an estimated $228K added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2019 was Arthur M. Cohen & Associates, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2019.